Gossamer Bio Inc. (GOSS) Prices 9.433M Share Common Offering at $13.25/Sh; Announces Pricing of $200M Convertible Senior Notes Due 2027

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. HOOD
8. DFTX
9. MU
10. IBM

Go back to Gossamer Bio Inc. (GOSS) Prices 9.433M Share Common Offering at $13.25/Sh; Announces Pricing of $200M Convertible Senior Notes Due 2027

Gossamer Bio Announces Pricing of Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027

May 19, 2020 1:24 AM EDT

SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the pricing of its underwritten public offering of 9,433,963 shares of its common stock at a price to the public of $13.25 per share and the pricing of $200.0 million aggregate principal amount of its 5.00% convertible senior notes due 2027. The aggregate gross proceeds to Gossamer from the offerings, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately... More